Alumis Inc.
ALMS
Rank in Stocks
#10338
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.25
Market Cap
$808.97M
Change (1 day)
2.12%
Change (1 year)
175.33%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
Earnings for Alumis Inc. (ALMS)
Earnings in Mar 2025 TTM: $-268.52M
According to Alumis Inc. latest financial reports the company's current earnings are $-268.52M. In 2023 the company made an earning of $-381.64M, a decrease compared to its 2022 earnings that were of $-64.77M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Alumis Inc. from 2021 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-268.52M | 8.17% |
| 2024 | $-248.23M | -34.96% |
| 2023 | $-381.64M | 489.21% |
| 2022 | $-64.77M | 54.81% |
| 2021 | $-41.84M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -2,064.46% |
US
|
|
| $-3.09B | 1,049.65% |
US
|
|
| $-4.02B | 1,395.70% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -826.45% |
NL
|
